First author of the article - Riten Kumar/LinkedIn
Jan 10, 2026, 14:40
Last day at ASH25 from Riten Kumar
Riten Kumar, Director of Thrombosis and Anticoagulation at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, shared on LinkedIn:
”Last day at ASH25 – interesting subgroup analysis from the RENOVE trial, increased CRNM bleeding with apixaban and aspirin, but not NSAIDs and Sriveda Boyala Kuntla’s excellent presentation on infection associated thrombosis, finished off with trainees – past, present and future!”
All from ASH25 featured in Hemostasis Today.
-
Jul 21, 2026, 15:02Sham Zamil: The Role of ABO Compatibility in Platelet Pooling
-
Jul 21, 2026, 13:43Dima Shulkin: Assessing AI-Driven Blood Test Screening for Colorectal Cancer
-
Jul 21, 2026, 13:24Benoit Mores: National Initiative Targets Better Cardiovascular Outcomes
-
Jul 21, 2026, 13:10Paolo Zamboni: Chronic Cerebrospinal Venous Insufficiency Hypothesis in Multiple Sclerosis
-
Jul 21, 2026, 13:05Danai Poutakidou։ The Diagnostic Pitfalls of Unexpected PT/INR Prolongation
-
Jul 21, 2026, 13:00Kefah Mokbel: Beyond Thromboprophylaxis – Enoxaparin’s Emerging Anticancer Signal
-
Jul 21, 2026, 12:56Emmanuel Velazquez-Alvarez: Bridging Innovation and Clinical Practice
-
Jul 21, 2026, 12:53Sandrine Bouteille: A Milestone Presentation at ISTH 2026
-
Jul 21, 2026, 12:40Kalled Musallam: A Comprehensive Review of Thalassemia